Tolvaptan activates the Nrf2/HO-1 antioxidant pathway through PERK phosphorylation

Tolvaptan, a vasopressin type 2 receptor antagonist initially developed to increase free-water diuresis, has been approved for the treatment of autosomal dominant polycystic kidney disease in multiple countries. Furthermore, tolvaptan has been shown to improve the renal functions in rodent models of...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Sci Rep
Glavni autori: Fujiki, Tamami, Ando, Fumiaki, Murakami, Kana, Isobe, Kiyoshi, Mori, Takayasu, Susa, Koichiro, Nomura, Naohiro, Sohara, Eisei, Rai, Tatemitsu, Uchida, Shinichi
Format: Artigo
Jezik:Inglês
Izdano: Nature Publishing Group UK 2019
Teme:
Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6592894/
https://ncbi.nlm.nih.gov/pubmed/31239473
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41598-019-45539-8
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items